GSK's Mo-Rez Cancer Treatment Demonstrates High Efficacy in Early Trials
GSK has unveiled encouraging early-stage results for its Mo-Rez cancer treatment, an antibody-drug conjugate (ADC) acquired from China's Hansoh Pharma in late 2023. In a trial involving 224 patients globally, including in the UK, Mo-Rez shrank or eliminated tumors in 62% of ovarian cancer patients where chemotherapy had failed and in 67% of those with endometrial cancer.
Promising Clinical Profile and Future Plans
Presented at the Society of Gynecologic Oncology's annual meeting in Puerto Rico, Hesham Abdullah, GSK's global head of cancer research and development, highlighted the treatment's potential. "With Mo-Rez we now have compelling evidence of a promising clinical profile," he stated, addressing the urgent need for new therapies in gynaecological cancers. Based on these results and data from a separate trial in China, GSK plans to advance directly to late-stage trials, with five clinical studies scheduled globally in the coming months.
Strategic Importance and Sales Projections
Mo-Rez is expected to become a blockbuster drug, with peak annual sales projected to exceed £2 billion. This aligns with GSK's ambitious 2031 sales target of £40 billion. The treatment represents a key asset in GSK's expanding oncology portfolio, which has grown from zero market drugs a few years ago to four approved medicines and 13 in clinical development today.
Leadership and Organizational Momentum
Under CEO Luke Miels, who took the helm on January 1, GSK has accelerated its drug development efforts. Abdullah praised Miels' leadership, noting increased pace and scientific courage within the organization. "The entire organisation is certainly really enjoying following this pace, the agility, and having the scientific courage," he remarked. Miels, formerly of AstraZeneca, Roche, and Sanofi-Aventis, has announced several deals since his appointment, reinforcing GSK's commitment to innovation in cancer research.
Context and Competitive Landscape
GSK, based in London, has recently gained recognition for its work on antimicrobial research, maintaining its position as one of only three major pharmaceutical companies investing in this area. However, it faces stiff competition from British rival AstraZeneca, which reported over £10 billion more in turnover than GSK's near-£33 billion last year. Despite being a vaccine specialist, GSK was slower to engage in Covid-19 vaccine development compared to AstraZeneca's early partnership with Oxford University.
Global Impact and Patient Statistics
Endometrial cancer affects 1.6 million women worldwide, with 417,000 new cases annually, while ovarian cancer impacts 843,000 people, with 240,000 new cases each year. The Mo-Rez trial reported minimal treatment discontinuations due to side-effects, with nausea being the most common issue, offering hope for improved patient outcomes in these challenging cancers.
